Skip to search formSkip to main contentSkip to account menu

MACOP-B regimen

Known as: Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen 
A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised… 
Highly Cited
2004
Highly Cited
2004
An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin… 
Review
2004
Review
2004
BACKGROUND Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. PATIENTS AND METHODS The… 
Highly Cited
1999
Highly Cited
1999
To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium… 
Highly Cited
1997
Highly Cited
1997
BACKGROUND We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by… 
Highly Cited
1993
Highly Cited
1993
BACKGROUND CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine… 
Highly Cited
1993
Highly Cited
1993
PURPOSE To evaluate the clinical features of presentation, the morphologic and immunohistochemical pattern, the modality of… 
Highly Cited
1992
Highly Cited
1992
PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation… 
Highly Cited
1990
Highly Cited
1990
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed… 
Highly Cited
1985
Highly Cited
1985
Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B…